PharmaTimes -
June 2023

Partly like it’s 1747!

I stress ‘partly’. Today’s clinical trials are evolving apace – perhaps more in the last four years than the previous four centuries.

The frst ofcial clinical trial unfolded in 1747, under the gaze of James Lind. He was concerned about the scourge of scurvy and thus analysed a cohort of patients, in an attempt to establish an efective therapy for the wider population. It was a landmark moment for mankind and became the touchpaper for frenetic probing, pondering and pontifcation as trials became the norm.

It was a bold move by the Homo sapien species to advance a new realm of existential curiosity – leaving their predecessors and, indeed, the rest of the animal kingdom in the dust. Humans were no longer accepting the hand they had been dealt – they wanted to alter the deck.

Clinical trials, however, have rarely been a true refection of society or the subgroups therein that most require input into research. Too often participation has been overwhelmingly white, male and middle class or designed for people who can navigate mind-boggling inconvenience.

Leveraging the potential of trials is about upholding diversity and inclusivity – increasing representation among diferent ethnicities, sexualities, backgrounds, religions, socio-economic statuses and geographical locations.

All these factors are part of a wider reboot of which James Lind would surely approve. Patients are becoming the stakeholders and experts in their own future.

We are the most gifted species in the history of the universe – but proving it is a gift we must never take for granted.

Enjoy the magazine!

June 2023 - magazine highlights

Thumbnail image for Game changer…

Game changer…

Oncology – what does it show us about the wider NHS in the years ahead?

Thumbnail image for Euro vision!

Euro vision!

The EU Commission’s proposals to revise pharmaceutical legislation is a step forward but there is more work to do

Thumbnail image for Event horizon

Event horizon

Three years on, how did the pandemic transform pharmacovigilance?

Thumbnail image for Still him

Still him

Editor John Pinching reviews Michael J. Fox’s remarkable new film about the reality of living with Parkinson’s disease

Thumbnail image for Chelsea roar

Chelsea roar

A spectacular ceremony paid homage to the stars while paving the way for an exciting future. Editor John Pinching reports from London

Latest jobs from #PharmaRole

View all

Project Director

Our client is an independent medical communications agency that works with publications, meetings, training materials,...
£65,000 - £75,000 yearly

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.